Grant Award Details

Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes
Grant Number: 
DISC2-12124
Project Objective: 
  • To enable the development of a combination therapeutic candidate composed of an HA hydrogel loaded with heparin nanoparticles, VEGF clusters and hESC-derived human islet-like organoids (HILO) to treat Type I Diabetes.
Disease Focus: 
Diabetes
Metabolic Disorders
Type 1 diabetes
Human Stem Cell Use: 
Embryonic Stem Cell
Award Value: 
$250,000
Status: 
Pre-Active

Grant Application Details

Application Title: 
  • Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes
Public Abstract: 

Research Objective

Functional human islet like organoids differentiated from human pluripotent stem cells.

Impact

Providing the immediate cell therapeutic candidate for clinical trial of diabetic patients.

Major Proposed Activities

  • Fabrication and characterization of the injectable immunomodulating and pro-angiogenic material components: HA hydrogel, heparin nanoparticles and VEGF clusters.
  • Generation of human islet like organoids from pluripotent stem cells for subcutaneous transplantation
  • Subcutaneous HILOs transplantation in pre-vasculature site in NOD-SCID mice.
  • Subcutaneous PD-L1 expressing HILOs transplantation in pre-vasculature site in Hu-PBMC-NSG mice
Statement of Benefit to California: 

The cell and technology products proposed by this diabetes therapeutic study will significantly improve future diabetes treatments in the State of California, particularly benefiting vulnerable populations, such as Hispanics, African-Americans, men, older populations, homeless individuals, and those of lower socioeconomic status. Additionally, this proposed research may create greater research employment opportunities in the South Bay, a region within Los Angeles County.